Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 10109

1.

Cartilage oligomeric matrix protein: A novel non-invasive marker for assessing cirrhosis and risk of hepatocellular carcinoma.

Norman GL, Gatselis NK, Shums Z, Liaskos C, Bogdanos DP, Koukoulis GK, Dalekos GN.

World J Hepatol. 2015 Jul 18;7(14):1875-83. doi: 10.4254/wjh.v7.i14.1875.

2.

Spectrum of biliary complications following live donor liver transplantation.

Simoes P, Kesar V, Ahmad J.

World J Hepatol. 2015 Jul 18;7(14):1856-65. doi: 10.4254/wjh.v7.i14.1856. Review.

3.

Hepatitis C cirrhosis: New perspectives for diagnosis and treatment.

Khullar V, Firpi RJ.

World J Hepatol. 2015 Jul 18;7(14):1843-55. doi: 10.4254/wjh.v7.i14.1843. Review.

4.

Spontaneous bleeding or thrombosis in cirrhosis: What should be feared the most?

Rodríguez-Castro KI, Antonello A, Ferrarese A.

World J Hepatol. 2015 Jul 18;7(14):1818-27. doi: 10.4254/wjh.v7.i14.1818.

5.

Autoimmune Hepatitis Triggered by Treatment With Pegylated Interferon α-2a and Ribavirin for Chronic Hepatitis C.

Rathi C, Pipaliya N, Choksi D, Parikh P, Ingle M, Sawant P.

ACG Case Rep J. 2015 Jul 9;2(4):247-9. doi: 10.14309/crj.2015.74. eCollection 2015 Jul.

6.

Prognostic models for alcoholic hepatitis.

Rahimi E, Pan JJ.

Biomark Res. 2015 Jul 21;3:20. doi: 10.1186/s40364-015-0046-z. eCollection 2015.

7.

Management options in decompensated cirrhosis.

Shah NL, Banaei YP, Hojnowski KL, Cornella SL.

Hepat Med. 2015 Jul 15;7:43-50. doi: 10.2147/HMER.S62463. eCollection 2015. Review.

8.

Liquiritigenin Protects Rats from Carbon Tetrachloride Induced Hepatic Injury through PGC-1α Pathway.

Zhang Y, He Y, Yu H, Ma F, Wu J, Zhang X.

Evid Based Complement Alternat Med. 2015;2015:649568. doi: 10.1155/2015/649568. Epub 2015 Jun 25.

9.

Diagnostic and Prognostic Values of Noninvasive Predictors of Portal Hypertension in Patients with Alcoholic Cirrhosis.

Cho EJ, Kim MY, Lee JH, Lee IY, Lim YL, Choi DH, Kim YJ, Yoon JH, Baik SK.

PLoS One. 2015 Jul 21;10(7):e0133935. doi: 10.1371/journal.pone.0133935. eCollection 2015.

10.

Efficacy and safety of sitagliptin for the treatment of diabetes mellitus complicated by chronic liver injury.

Asakawa M, Mitsui H, Akihisa M, Sekine T, Niitsu Y, Kobayashi A, Miyake A, Hashimoto N, Kawamura M, Ogawa Y.

Springerplus. 2015 Jul 15;4:346. doi: 10.1186/s40064-015-1135-z. eCollection 2015.

11.

MicroRNA301 is a potential diagnostic biomarker for hepatocellular cancer.

He K, Hu Z, Ruan J, Ma Q, Zhong F, Cheng X, Sun S, Zhou J.

Int J Clin Exp Pathol. 2015 May 1;8(5):5603-8. eCollection 2015.

12.

Assessment of cardiovascular physiology using dobutamine stress cardiovascular magnetic resonance reveals impaired contractile reserve in patients with cirrhotic cardiomyopathy.

Sampaio F, Lamata P, Bettencourt N, Alt SC, Ferreira N, Kowallick JT, Pimenta J, Kutty S, Fraga J, Steinmetz M, Bettencourt P, Gama V, Schuster A.

J Cardiovasc Magn Reson. 2015 Jul 18;17(1):61. doi: 10.1186/s12968-015-0157-6.

13.

Association between Liver Fluke Infection and Hepatobiliary Pathological Changes: A Systematic Review and Meta-Analysis.

Xia J, Jiang SC, Peng HJ.

PLoS One. 2015 Jul 17;10(7):e0132673. doi: 10.1371/journal.pone.0132673. eCollection 2015.

14.

Suppression of postsurgical recurrence of hepatocellular carcinoma treated with autologous formalin-fixed tumor vaccine, with special reference to glypican-3.

Kawashima I, Kawashima Y, Matsuoka Y, Fujise K, Sakai H, Takahashi M, Yoshikawa T, Nakatsura T, Ishihara T, Ohno T.

Clin Case Rep. 2015 Jun;3(6):444-7. doi: 10.1002/ccr3.279. Epub 2015 Apr 17.

15.

Alterations in Ultrasound Scattering Following Thermal Ablation in <i>ex vivo</i> Bovine Liver.

Rubert N, Varghese T.

IEEE Int Ultrason Symp. 2014 Sep 6;2014:1904-1907.

16.

Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.

Al-Hamoudi W, Elsiesy H, Bendahmash A, Al-Masri N, Ali S, Allam N, Al Sofayan M, Al Bahili H, Al Sebayel M, Broering D, Saab S, Abaalkhail F.

World J Gastroenterol. 2015 Jul 14;21(26):8140-7. doi: 10.3748/wjg.v21.i26.8140.

17.

A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2014: The 49th Annual Meeting of the European Association for the Study of the Liver • April 9-13, 2014 • London, United KingdomSpecial Reporting on:• SAPPHIRE II: Phase 3 Placebo-Controlled Study of Interferon-Free, 12-Week Regimen of ABT-450/R/ABT-267, ABT-333, and Ribavirin in Treatment-Experienced Adults With Hepatitis C Virus Genotype 1• All Oral Fixed-Dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: the Phase 3 ION-1 Study• PEARL-III: 12 Weeks of ABT-450/R/267 + ABT-333 Achieved SVR in &gt;99% of 419 Treatment-Naive HCV Genotype 1B-Infected Adults With or Without Ribavirin• Results of the Phase 2 Study M12-999: Interferon-Free Regimen of ABT-450/R/ABT-267 + ABT-333 + Ribavirin in Liver Transplant Recipients With Recurrent HCV Genotype 1 Infection• Sofosbuvir and Ribavirin for the Treatment of Chronic HCV With Cirrhosis and Portal Hypertension With and Without Decompensation: Early Virologic Response and Safety• All-Oral Dual Therapy With Daclatasvir and Asunaprevir in Patients With HCV Genotype 1B Infection: Phase 3 Study Results• Sofosbuvir/Ledipasvir Fixed Dose Combination Is Safe and Effective in Difficult-to-Treat Populations Including Genotype-3 Patients, Decompensated Genotype-1 Patients, and Genotype-1 Patients With Prior Sofosbuvir Treatment Experience• Sofosbuvir and Ribavirin for the Treatment of Recurrent Hepatitis C Infection After Liver Transplantation: Results of a Prospective, Multicenter StudyPLUS Meeting Abstract Summaries With Expert Commentary by: Steven L. Flamm, MDChief, Liver Transplantation ProgramProfessor of Medicine and SurgeryNorthwestern University Feinberg School of MedicineChicago, Illinois.

[No authors listed]

Gastroenterol Hepatol (N Y). 2014 Jun;10(6 Suppl 2):1-19. No abstract available.

18.

Loss of FGF21 in diabetic mouse during hepatocellular carcinogenetic transformation.

Zhang Q, Li Y, Liang T, Lu X, Liu X, Zhang C, Jiang X, Martin RC, Cheng M, Cai L.

Am J Cancer Res. 2015 Apr 15;5(5):1762-74. eCollection 2015.

19.

Incidental Chylous Ascites at the Time of Cesarean Section.

Thompson KA, Al Khabbaz A.

Case Rep Obstet Gynecol. 2015;2015:530210. doi: 10.1155/2015/530210. Epub 2015 Jun 15.

20.

Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma.

DA Fonseca LG, Barroso-Sousa R, Bento AD, Blanco BP, Valente GL, Pfiffer TE, Hoff PM, Sabbaga J.

Mol Clin Oncol. 2015 Jul;3(4):793-796. Epub 2015 Apr 2.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk